ANTI-ErbB2 ANTIBODIES

• US 20110033460A1
• Filed: 10/22/2010
• Published: 02/10/2011
• Est. Priority Date: 10/18/1996
• Status: Abandoned Application

• Current Assignee: Brian M. Fendly, Gail Dianne Phillips, Jonathan W. Uhr, Richard H. Scheuermann
• Original Assignee: Brian M. Fendly, Gail Dianne Phillips, Jonathan W. Uhr, Richard H. Scheuermann
• Inventors: Fendly, Brian M., Scheuermann, Richard H., Uhr, Jonathan W., Phillips, Gail Dianne
• Application Number:
  US12/910,590
• Publication Number:
  US 20110033460A1
• Time in Patent Office: Days
• US Class Current: 424/133.1
• CPC Class Codes: A61J 1/00 Containers specially adapted for medical or pharmaceutical purposes capsules or the like for oral use A61J3/07; specially adapted for surgical or diagnostic appliances or instruments A61B50/30; containers for radioactive substances G21F5/00
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/507 Comprising a combination of two or more separate antibodies
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: B65D 25/205 Means for the attachment of labels, cards, coupons or the like; cards or coupons for the other types of rigid or semi-rigid containers B65D25/36 takes precedence
• CPC Class Codes: C07K 16/2863 against receptors for growth factors, growth regulators
• CPC Class Codes: C07K 16/3015 Breast
• CPC Class Codes: C07K 16/3069 Reproductive system, e.g. ovaria, uterus, testes, prostate
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 17/00 Carrier-bound or immobilised peptides carrier-bound or immobilised enzymes C12N11/00; Preparation thereof
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/567 Framework region [FR]
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 2333/71 for growth factors; for growth regulators
• CPC Class Codes: G01N 2333/912 transferring phosphorus containing groups, e.g. kinases (2.7)
• CPC Class Codes: G01N 33/573 : for enzymes or isoenzymes
• CPC Class Codes: G01N 33/5748 : involving oncogenic proteins

Abstract

Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.

Claims

1-41. -41. (canceled)

42. A method of treating cancer comprising administering to a human subject with cancer characterized by overexpression of the ErbB2 receptor a first antibody that binds Domain 1 (SEQ ID NO:

1) of ErbB2 and thereby induces cell death in cancer cells overexpressing ErbB2, or an antigen-binding fragment of said first antibody, and a second antibody that binds ErbB2 at a different domain than Domain 1 and inhibits growth of cancer cells overexpressing ErbB2, or an antigen-binding fragment of said second antibody.

43. The method of claim 42, wherein the first antibody binds epitope 7C2/7F3 (SEQ ID NO:

2) of ErbB2.

44. The method of claim 42, wherein the first antibody comprises CDRs of antibody 7C2 or 7F3.

45. The method of claim 42, wherein the first antibody induces apoptosis in said cells.

46. The method of claim 42 wherein the second antibody comprises CDRs of antibody 4D5.

47. The method of claim 42, wherein the first antibody comprises CDRs of antibody 7C2 or 7F3 and the second antibody comprises CDRs of antibody 4D5.

48. The method of claim 42, wherein the first and the second antibodies are chimeric, humanized or human.

49. The method of claim 42, wherein the cancer is breast cancer.

50. The method of claim 49, wherein administration is performed intravenously as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerobrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes.

51. The method of claim 50 wherein administration is performed intravenously.